Patents by Inventor Kota Zama

Kota Zama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid having an anti-metabolic syndrome effect
    Patent number: 8889648
    Abstract: The problem of the present invention is to prove a medicament for decreasing body weigh, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a method for screening a medicament for ameliorating obesity and fatty liver. The problem is solved by a method comprising measuring an activity of a candidate material for inhibiting a sphingomyelin synthetase wherein if the candidate material has an activity for inhibiting a sphingomyelin synthetase, the candidate material is judged to have at least one function selected from the consisting of an anti-obesity drug, a drug for decreasing visceral fat, a drug for treating fatty liver and an agent for increasing adiponectin expression.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: November 18, 2014
    Assignees: National University Corporation Hokkaido University, Shionogi & Co., Ltd.
    Inventors: Susumu Mitsutake, Kota Zama, Yasuyuki Igarashi, Tetsuya Yoshida, Yoshikazu Tanaka, Hiroshi Takemoto
  • NUCLEIC ACID HAVING AN ANTI-METABOLIC SYNDROME EFFECT
    Publication number: 20130231383
    Abstract: The problem of the present invention is to prove a medicament for decreasing body weigh, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a method for screening a medicament for ameliorating obesity and fatty liver. The problem is solved by a method comprising measuring an activity of a candidate material for inhibiting a sphingomyelin synthetase wherein if the candidate material has an activity for inhibiting a sphingomyelin synthetase, the candidate material is judged to have at least one function selected from the consisting of an anti-obesity drug, a drug for decreasing visceral fat, a drug for treating fatty liver and an agent for increasing adiponectin expression.
    Type: Application
    Filed: September 21, 2011
    Publication date: September 5, 2013
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Susumu Mitsutake, Kota Zama, Yasuyuki Igarashi, Tetsuya Yoshida, Yoshikazu Tanaka, Hiroshi Takemoto
  • AMELIORATION OF METABOLIC SYNDROME USING PHYSIOLOGICAL FUNCTIONS OF SPHINGOMYELIN SYNTHASE SMS2, OR SCREENING METHODS FOR AMELIORATING AGENTS
    Publication number: 20120315658
    Abstract: Disclosed is a method for screening for a medicinal agent that can decrease a body weight, a medicinal agent that can reduce a visceral fat, a medicinal agent that can reduce a triglyceride in the liver, and a medicinal agent that can ameliorate obesity and fatty liver. The method involves a step of measuring the inhibitory activity of a candidate substance on a sphingomyelin synthase, wherein the candidate substance is determined to have at least one function selected from the group consisting of an anti-obesity agent, a visceral fat-reducing agent, a fatty liver-treating agent and an adiponectin expression enhancer when the candidate substance has an inhibitory activity on the sphingomyelin synthase.
    Type: Application
    Filed: September 22, 2010
    Publication date: December 13, 2012
    Applicants: Shionogi & Co., Ltd., National University Corporation Hokkaido University
    Inventors: Susumu Mitsutake, Yasuyuki Igarashi, Kota Zama, Tetsuya Yoshida, Yoshikazu Tanaka, Hiroshi Takemoto